Celldex Therapeutics, Inc. (CLDX) Earnings History
Annual and quarterly earnings data from 1987 to 2025
Loading earnings history...
CLDX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CLDX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 100.0% | -19160.0% | -17253.3% |
| 2024 | -2229.8% | -2778.9% | -2248.8% |
| 2023 | -1614.5% | -2245.3% | -2054.8% |
| 2022 | -3389.9% | -4889.0% | -4765.6% |
| 2021 | -1046.2% | -1531.8% | -1516.0% |
Download Data
Export CLDX earnings history in CSV or JSON format
Free sign-in required to download data
Celldex Therapeutics, Inc. (CLDX) Earnings Overview
As of May 7, 2026, Celldex Therapeutics, Inc. (CLDX) reported trailing twelve-month net income of -$259M, reflecting -59.2% year-over-year growth. The company earned $-3.89 per diluted share over the past four quarters, with a net profit margin of -17253.3%.
Looking at the long-term picture, CLDX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 1989.
Celldex Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), ARDX (-$58M net income, -15.1% margin), RCUS (-$369M net income, -142.9% margin), CLDX has comparable earnings metrics. Compare CLDX vs IMVT →
CLDX Earnings vs Peers
Earnings metrics vs comparable public companies
CLDX Historical Earnings Data (1987–2025)
39 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$259M | -63.9% | -$287M | $-3.90 | -17253.3% | -19160.0% |
| 2024 | -$158M | -11.6% | -$195M | $-2.45 | -2248.8% | -2778.9% |
| 2023 | -$141M | -25.9% | -$155M | $-2.92 | -2054.8% | -2245.3% |
| 2022 | -$112M | -59.3% | -$115M | $-2.40 | -4765.6% | -4889.0% |
| 2021 | -$71M | -18.0% | -$71M | $-1.64 | -1516.0% | -1531.8% |
| 2020 | -$60M | -17.5% | -$63M | $-2.02 | -805.9% | -854.1% |
| 2019 | -$51M | +66.3% | -$55M | $-3.51 | -1424.0% | -1540.2% |
| 2018 | -$151M | -62.5% | -$156M | $-14.48 | -1585.1% | -1640.1% |
| 2017 | -$93M | +27.6% | -$122M | $-10.86 | -730.1% | -953.7% |
| 2016 | -$129M | -1.0% | -$133M | $-18.99 | -1894.0% | -1958.7% |
See CLDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLDX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCLDX — Frequently Asked Questions
Quick answers to the most common questions about buying CLDX stock.
Is CLDX growing earnings?
CLDX EPS fell to $-3.89, with earnings declining -59.2%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-259M.
What are CLDX's profit margins?
Celldex Therapeutics, Inc. net margin is -17253.3%, with operating margin at -19160.0%. Below-average margins reflect competitive or cost pressures.
How consistent are CLDX's earnings?
CLDX earnings data spans 1987-2025. The declining earnings trend is -59.2% YoY. Historical data enables comparison across business cycles.